Puretech Health Stock Price, News & Analysis

Follica announced encouraging results from a pilot study on treating female pattern hair loss (FPHL) using its proprietary Hair Follicle Neogenesis (HFN) device. Enrolling 11 women, the study demonstrated significant hair growth over four months, with all participants reporting improvements. The device stimulates stem cells to develop new hair follicles, complemented by a topical drug. Despite the small sample size, the outcomes highlight a notable treatment gap for women with few options available. Follica plans to advance to Phase 3 development in 2021, furthering its commitment to innovative hair loss solutions.

Follica, a biotechnology firm focused on treating hair loss, announced positive results from a pilot study published in the International Journal of Women’s Dermatology. The study, led by Dr. Maryanne M. Senna, involved 11 women with female pattern hair loss (FPHL), showing significant hair growth after six treatments using the proprietary Hair Follicle Neogenesis (HFN) device. All participants reported improvement on the physician-assessed Sinclair scale. Follica aims to advance to Phase 3 trials in 2021, following successful studies in treating male androgenetic alopecia.

PureTech Health plc (LSE: PRTC, Nasdaq: PRTC) noted the publication of a pilot study by its Founded Entity, Follica, in the International Journal of Women’s Dermatology. The study evaluated a treatment that promoted hair growth in women with female pattern hair loss (FPHL). Out of 11 participants, 10 reported improvements in hair growth after six treatments using Follica's proprietary Hair Follicle Neogenesis (HFN) device. The pilot study's results are viewed as encouraging, suggesting the need for larger studies to validate the findings.

PureTech Health (LSE: PRTC, Nasdaq: PRTC) has initiated a global Phase 2 trial for LYT-100, aimed at treating Long COVID respiratory complications. The trial follows a successful Phase 1 study demonstrating LYT-100's tolerability and favorable pharmacokinetic profile. LYT-100, a deuterated form of pirfenidone, targets inflammation and fibrosis associated with lung conditions, including Long COVID. The Phase 2 trial will assess efficacy, safety, and tolerability in adults, with results expected in the latter half of 2021. This research addresses a critical public health need as many COVID-19 survivors continue to experience respiratory issues.

PureTech Health (LSE: PRTC, Nasdaq: PRTC) is hosting its inaugural R&D Day on December 11, 2020, at 9:00 a.m. ET. This virtual event will highlight the company's advancements in lymphatics and immune pathways, featuring insights on its product candidates LYT-100 and LYT-200. Experts, including renowned scientists and physicians, will present their perspectives on fibrotic, inflammatory conditions, and immuno-oncology. The event aims to showcase PureTech's innovative therapeutic approaches and progress within its Wholly Owned Pipeline, which includes four product candidates.

PureTech Health (LSE: PRTC, Nasdaq: PRTC) announced the appointment of Troy Ignelzi as an independent board member of its Founded Entity, Vedanta Biosciences. With over 25 years in the life sciences sector, Ignelzi has experience in finance and operations, playing a crucial role in several IPOs. He currently serves as CFO at Karuna Therapeutics and will chair Vedanta's Audit Committee. This appointment aims to strengthen Vedanta's financial strategy as it advances its innovative microbiome-based therapies.

Vedanta Biosciences has appointed Troy Ignelzi as an independent member of its Board of Directors. Ignelzi brings over 25 years of experience in finance and operations, playing a significant role in seven IPOs. Currently the CFO of Karuna Therapeutics, he has previously led financial transformations at multiple biopharmaceutical companies. His expertise is expected to guide Vedanta's financial strategy during its upcoming development phase. The company is focused on therapies derived from the human microbiome to treat immune-mediated diseases.

PureTech Health plc (LSE: PRTC, Nasdaq: PRTC) has successfully completed a Phase 1 multiple ascending dose and food effect study for LYT-100 (deupirfenidone), demonstrating a favorable tolerability and pharmacokinetic profile. LYT-100 aims to treat inflammation, fibrosis, and lymphatic disorders, showing potential for improved tolerability compared to the marketed drug pirfenidone. The study indicated LYT-100 was well-tolerated at doses up to 1000 mg BID, allowing for future twice-a-day dosing. PureTech plans to initiate Phase 2 trials for Long COVID and lymphedema this quarter.

PureTech Health (LSE: PRTC, Nasdaq: PRTC) announced key upcoming presentations at virtual investor conferences. The presentations will feature founder and CEO Daphne Zohar and Chief Innovation Officer Eric Elenko. Key dates include the Jefferies 2020 Virtual London Healthcare Conference on November 18, 2020, at 9:05 AM EST, Piper Sandler's Annual Virtual Healthcare Conference available from November 23, and Evercore ISI's HealthCONx Conference on December 3, 2020, at 4:20 PM EST. The company focuses on developing innovative treatments for serious diseases, boasting a diverse pipeline of 24 candidates.